The “Temporary Recommendations for Use”: A dual-purpose regulatory framework for off-label drug use in France  by Degrassat-Théas, Albane et al.
HT
r
A
J
a
l
b
F
c
a
A
R
R
A
K
P
T
O
M
b
a
F
a
(
0
lHealth Policy 119 (2015) 1399–1405
Contents lists available at ScienceDirect
Health  Policy
journa l h om epa ge: www.elsev ier .com/ locate /hea l thpol
ealth  Reform  Monitor
he  “Temporary  Recommendations  for  Use”:  A  dual-purpose
egulatory  framework  for  off-label  drug  use  in  France
lbane  Degrassat-Théasa,b,c,∗, Franc¸ ois  Bocqueta,b,c,  Martine  Sinègrec,
érôme  Peignéa,b,  Pascal  Paubelb,c
Law and Health Economics Department, Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, 4 avenue de
’Observatoire, 75006 Paris, France
Institut Droit et Santé (INSERM UMR-S 1145), Paris Descartes University, Sorbonne Paris Cité, 45 rue des Saints-Pères, 75006 Paris,
rance
Pharmacy Department, General Agency of Equipments and Health Products (AGEPS), 7 rue du Fer-à-Moulin, 75005 Paris, France
 r  t  i c  l  e  i  n  f  o
rticle history:
eceived 17 April 2015
eceived in revised form 31 August 2015
ccepted 14 September 2015
eywords:
olicy development
emporary Recommendations for Use
ff-label drug use
arketing authorization
a  b  s  t  r  a  c  t
In 2012,  following  the Mediator® (benﬂuorex)  scandal,  France  displayed  the  ambitious  goal
to implement  a regulatory  framework  for  controlling  off-label  drug  use:  the  “Temporary
Recommendations  for Use”  (RTUs).  It aims  to regulate  the  use  of  pharmaceuticals  outside
the scope  of  a  marketing  authorization  (MA)  by establishing  a framework  for  patient  mon-
itoring  and  data  collection.  This  is  intended  to ensure  that  the  beneﬁt/risk  ratio is  favorable
for  the  indication  approved  by  the  RTU.  The  granting  of  an  RTU  enables  the  reimburse-
ment  of  off-label  drug  use  and  encourages  pharmaceutical  companies  to expand  their  MA.
Between 2012  and  2014,  the  regulator  framework  for RTUs  was  amended  twice  in  order
to allow  the  bypassing  of an  MA  for economic  reasons,  when  a  licensed  alternative  drug
exists  (so far, this  is  only  illustrated  by  the  bevacizumab  (Avastin®)/ranibizumab  (Lucentis®)
case).  The  primary  purpose  of  the RTU  framework  is interesting  by  implementing  an origi-
nal national  control  for  off-label  uses  that respond  to  a public  health  need.  The  secondary
purpose  is more  controversial  as it promotes  off-label  use. This  has  raised  legal  issues  and
has created  a ground  for litigation  between  pharmaceutical  ﬁrms  and  health  authorities.
RTUs  provide  an interesting  example  for  other  countries  that  are  exploring  the  possibility  of
regulating  off-label  drug  use.  At the  same  time,  the  processes  surrounding  the  implemen-
tation of RTUs  illustrate  the  difﬁculties  of  public  policies  to balance  public  health  needs,
safety  and  economic  goals.
©  2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
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To ensure patient access to drugs with proven quality
and presenting a favorable beneﬁt/risk proﬁle, the Euro-
pean Union (EU) has established a tight safety net. No
medicinal product may  be commercialized in a Member
State unless the competent authorities of that Member
State have issued a Marketing Authorization (MA) [1].
Additionally, national policies may  require pharmaceuti-
cal companies to obtain price approval and reimbursement
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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eligibility for the approved indications. However, in “real
life” situations, physicians may  lawfully prescribe licensed
medicines outside the provisions listed in the summary
of product characteristics (different indications, adminis-
tration options, dose regimens, etc.), provided that they
disclose the risks and the beneﬁts to their patients. This
off-label drug use is quite widespread (a study conducted
in the United States estimates that approximately 21%
of uses for commonly prescribed medicines are off-label
[2]), especially in therapeutic areas where scientiﬁc knowl-
edge goes faster than administrative procedures (oncology
for instance), or for speciﬁc subgroups of patients that
are hardly included in clinical trials for ethical, legal or
technical reasons (such as pediatric and elderly patients,
pregnant women, psychiatric patients, and rare diseases),
or in the case of “old” licensed-drugs for which pharma-
ceutical ﬁrms have no economic incentives to perform an
expensive trial in order to expand their MA.
Recently, a control framework for medically justiﬁed
off-label prescriptions has been implemented in France fol-
lowing the Mediator® (benﬂuorex) scandal in 2011. This
event highlighted the risks of an off-label use and gave
the opportunity to the French health authorities to reg-
ulate off-label prescriptions for safety concerns [3]. In
fact, benﬂuorex, which was approved for treating dia-
betes, was commonly used as an anorectic drug and caused
sometimes-fatal valvular heart diseases. The public had
high expectations toward the French government to imple-
ment a major change in the regulatory system. Thus, the
Act No 2011-2012 of the 29th December 2011 reinforcing
the safety of medicines and health products [4] addresses
the ambitious goal of controlling off-label drug use. The
Act explicitly recognizes the right of physicians to pre-
scribe drugs outside of their label for use by an individual
patient, under their direct personal responsibility and in
the patient’s interest. It also introduces into French law a
second and unique derogating provision pursuant to article
L.5121-12-1 of the French Public Health Code: a regulatory
process called “Temporary Recommendations for Use”
(Recommandations Temporaires d’Utilisation–RTUs) [5].
In less than three years, the initial regulatory framework
for RTUs has been amended substantially twice in order to
allow the bypassing of an MA  for economic reasons. Indeed,
in addition to responding to the primary health safety goal,
the RTUs have appeared to potentially counteract the use
of MAs  as a market segmentation tool by pharmaceutical
ﬁrms. In this paper, we provide an overview of the issues
raised by a framework aimed to control off-label drug use
from the experience of the implementation of the RTUs in
France.
2. The aim of the initial framework: secure off-label
drug use
RTUs aim to secure off-label drug use for a limited period
of time in which ﬁrms must supervise the drug use and
are encouraged to expand their MA.  RTUs are issued at the
national level by the French national agency of medicine
and health product safety (Agence Nationale de Sécurité
du Médicament et des produits de santé – ANSM). Prior
to the implementation of RTUs, legalized and reimbursedlicy 119 (2015) 1399–1405
off-label drug use was limited to innovative and costly
drugs administered in hospitals and some drugs indicated
in rare diseases or long-lasting conditions. The RTU has
enlarged the scope of authorized and reimbursed off-label
drug use, as any given drug with a MA  in a different indica-
tion may  be qualiﬁed to beneﬁt from this exemption. It is
worth stressing that RTUs must be distinguished from the
French compassionate-use program: “Temporary Autho-
rizations for Use” (Autorisations Temporaires d’Utilisation –
ATUs), which aims at facilitating early access to new drugs
without any MA in France.
At its very beginning, an RTU could be granted if -and
only if- there was  no authorized equivalent on the national
market. When the need to regulate the use of a drug outside
the scope of its MA  arises (ﬁrms cannot request an RTU),
the ANSM assesses the data provided by the manufacturer
and academic scientiﬁc studies and, in the case of a posi-
tive opinion, establishes the nature of the patient follow-up
required: efﬁcacy and safety data to be collected, real con-
dition of use and schedule for reporting data to the agency
[6,7] (Fig. 1). Such a follow-up may  be part of a convention
signed between the ANSM and the pharmaceutical ﬁrm,
which must fund this patient monitoring. If necessary, the
convention includes the pharmaceutical company’s com-
mitment to submit a request to extend the MA  within a time
frame speciﬁed by the ANSM. Besides, an RTU is granted for
a molecule for the designated indication. As a consequence,
several licensed drugs, including generics and originator
drugs, may  be covered by the same RTU. There was  origi-
nally a three-year limit to the grant of an RTU. However, the
ANSM emphasizes that if RTUs ensure a period of observa-
tion and data collection, only clinical trials could provide
robust evidence to obtain a MA.
After active lobbying of physicians and patients, the ﬁrst
RTU has been granted in 2014 for baclofen, which has been
commercialized in France for years in the treatment of
spasticity. The recent huge enthusiasm for this drug in alco-
hol dependence [8], notably following a best-selling book
by a physician who described the story of his alcohol addic-
tion and the success of the use of baclofen, has urged the
need to objectively describe its therapeutic beneﬁts with
respect to the risks. Therefore, this ﬁrst RTU fulﬁlls the
initial criteria of the framework and aims at limiting the
spread of off-label drug use in order to avoid patient expo-
sure to old drugs that have been poorly assessed in those
indications.
The following four RTUs, which have been granted
for tocilizumab (RoActemra®), inﬂiximab (Remicade®),
bortezomib (Velcade®) and thalidomide (Thalidomide
Celgene®) (Table 1), have been issued for drugs in rare
diseases. They also address a public health need by permit-
ting fast-track access to innovative drugs or by overcoming
difﬁculties to conduct clinical trials for certain population
subgroups, which is more akin to a compassionate use.
3. A new purpose of the RTU framework: an
economic goalThe position taken by all stakeholders, including health
care authorities and pharmaceutical ﬁrms, is ambiguous
toward off-label drug use [9,10]. On the one hand, health
A. Degrassat-Théas et al. / Health Policy 119 (2015) 1399–1405 1401
Fig. 1. The different steps to obtain an RTU. ANSM: the French national agency of medicine and health product safety (Agence Nationale de Sécurité du
Médicament et des produits de santé); HAS: the high health authority (Haute Autorité de Santé); INCa: the National Cancer Institute (Institut National du
Cancer);  MA: Marketing Authorization; RTU: temporary recommendations for use (Recommandations Temporaires d’Utilisation); UNCAM: the institution in
charge of Social Security Insurance (Union Nationale des Caisses d’Assurance Maladie). Note: The main changes to the framework are in bold and underlined.
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Table 1
Main characteristics of the current RTUs (for more information, see the ANSM’s website: www.ansm.sante.fr).
Drug MA  holder Starting date of
the RTU
Therapeutic area
covered by the RTU
Population targeted
by the RTU
Therapeutic area
covered by the MA
Commercialization
date
Unit price (excluding tax)
Baclofen (Lioresal® and
baclofene Zentiva®)
Novartis and
Sanoﬁ
March, the
17th of 2014
Alcohol dependence Tens of thousands Spasticity April 1974
January 2006
Tablets of 10 mg:
Lioresal®: 4.620D per 50 tablets
Baclofene Zentiva®: 1.940D per
30 tablets
Tocilizumab
(RoActemra®)
Roche April, the 7th of
2014
Castleman disease Around ten new
patients per year
Rheumatoid arthritis August 2009 20 mg/ml  concentrate for
solution for infusion:
133.216D per 4 ml vial
333.040D per 10 ml vial
666.080D per 20 ml vial
Inﬂiximab (Remicade®) MSD  October, the
27th of 2014
Takayasu arteritis 90–120 patients Psoriatic arthritis,
Rheumatoid arthritis,
Ulcerative colitis,
Crohn’s disease
Psoriasis
Ankylosing spondylitis
January 2000 100 mg powder for concentrate
for solution for infusion:
434.403D per vial
Bortezomib (Velcade®) Janssen-Cilag April, the 2nd
of 2015
AL amyloidosis
Randall disease
3200 patients Multiple Myeloma
Mantle cell lymphoma
June 2004 Powder for solution for
injection:
298.627D per vial of 1 mg
1043.850D per vial of 3.5 mg
Thalidomide
(Thalidomide
Celgene®)
Celgene June, the 8th of
2015
Severe aphtous
Cutaneous lupus
erythematosus
Severe and acute
erythema nodosum
leprosum
Severe and active
Crohn’s disease
among children
above 6 years old
Around 1000 in
cutaneous
indications; difﬁcult
to estimate eligible
patients to the RTU in
Chron’s disease
Multiple Myeloma 1950’s 11.900D per capsule of 50 mg
Bevacizumab
(Avastin®)
Roche September, the
1st of 2015
Wet  age-related
macular degeneration
Between 41,700 and
44,800 patients
Colorectal cancer
Breast cancer
Non-small cell lung
cancer
Renal cancer
Ovarian cancer
April 2005 25 mg/ml concentrate for
solution for infusion:
248.311D per 4 ml vial
913.748D  per 16 ml  vial
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are authorities should limit off-label use in order to ensure
 patient access to approved drugs, which went through a
tructured process of licensing. Furthermore, pharmaceu-
ical ﬁrms must not encourage off-label use, as they are
esponsible of the use of their drug. The respect of their MA
ay  prevent competition and contributes to set high prices
hat guarantee a return on investment of expensive clinical
rials. On the other hand, off-label drug use can increase
heir revenues. In addition, regulation authorities would
ike to avoid market segmentation and anti-competitive
ractices due to MA  that are designed for more and more
ell-deﬁned target populations and that lead to a high bar-
aining power for pharmaceutical ﬁrms. In fact, what has
ot been foreseen at the time of the RTU implementation is
he off-label use that can generate ﬁnancial savings for the
ational health insurance. In this sense, the French health
uthorities have amended the RTU framework in order to
uthorize the reimbursement of a drug used outside its MA,
espite the existence of licensed therapeutic alternatives
ecause of the burden of the licensed drugs on the health-
are system. So far, this “economic RTU” is illustrated by the
evacizumab (Avastin®)/ranibizumab (Lucentis®) case.
It is worth reminding the context in which this particu-
ar RTU arise. Bevacizumab, for which Roche is the holder
f several MA  in cancer, is largely used off-label in the
reatment of wet age-related macular degeneration (AMD).
his drug was already prescribed in AMD  before the launch
f two licensed drugs for this condition: ranibizumab, for
hich Novartis holds a MA  in EU since 2007, and aﬂiber-
ept (Eylea®), which is marketed by Bayer Pharma and
hich is authorized for use in EU for AMD  since 2012.
he risk/beneﬁt ratio of bevacizumab in AMD  is presumed
avorable based on the efﬁcacy and safety data available
at least two recent Cochrane meta-analyzes [11,12] and
esults of prospective randomized studies, which were con-
ucted independently of any funding by pharmaceutical
ompanies in different countries, France included [13]).
espite these results, Roche has decided not to pursue
 MA  for bevacizumab in AMD  anywhere in the world.
oche and Novartis are suspected of collusion regarding
his strategic position. In fact, what has led to serious polit-
cal concerns is that ranibizumab costs substantially more
han bevacizumab, about twenty times more expensive.
urthermore, Genentech, a member of the Roche group,
eveloped both bevacizumab and ranibizumab, which is
 monoclonal antibody fragment of bevacizumab. This
ase is an international issue [14]. In Italy, a 183 million
uros ﬁne was imposed in 2014 to Novartis and Roche
or allegedly prevent the use of bevacizumab in AMD  by
rightening physicians about safety issues. In April 2014,
he French competition authority raided companies sus-
ected of having implemented anti-competitive practices
n drugs preventing AMD. The results of the investigation
re not known so far.
In France, the economic burden of ranibizumab is illus-
rated by the D430 million amount reimbursed by the
rench health social security for ranibizumab in 2013 [15].
his drug holds the top of the ranking of reimbursement
or pharmaceuticals in the ambulatory care sector. Then,
o permit and reimburse the use of bevacizumab in AMD,
he Social Security Financing Act of 2013 [16] introduced alicy 119 (2015) 1399–1405 1403
new derogation for granting an RTU. RTUs may  be issued
if such an off-label drug use may  avoid a signiﬁcant ﬁnan-
cial impact to the national health insurance, even though
an authorized equivalent is available on the French mar-
ket. The related decree has never been enacted since the
French Council of State seriously questioned the lawfulness
of such an economic argument to bypass the MA  follow-
ing two  recent judgments of the European Court of Justice
(ECJ). Derogations to the MA (as it is permitted by Para-
graph 1 Article 5 of the European Directive 2001/83/EC)
should be applicable in exceptional cases on the basis of
purely therapeutic considerations (and thus to the exclu-
sion of economic and other considerations). According to
the Court, a physician may  prescribe a drug which does
not have a valid MA in the EU and for which there is no
authorized equivalent on the national market or which is
unavailable on that market in order to fulﬁll special needs,
in response to a bona ﬁde unsolicited order, and for use by
an individual patient under his direct personal responsi-
bility [17]. On the one hand, Article 5(1) cannot be relied
upon when medicinal products having the same active sub-
stances, dosage and form as those the doctor considers that
he must prescribe to treat his patients, are already autho-
rized and available on the national market (as ruled by the
Court to avoid the use of generics without MA  in Poland
[18]). On the other hand, this judgment opens the right
to prescribe bevacizumab in AMD  (provided therapeutic
considerations speciﬁc to the patients) since the active
pharmaceutical ingredients of Avastin® and Lucentis® are
different.
Consequently, in August 2014, the amended Social
Security Financing Act of 2014 abandoned all explicit eco-
nomical arguments and expanded the rules relating to the
creation of RTUs [19]. Using the ECJ’s formulation, RTUs
may  be issued even if there is an available therapeutic
alternative, provided that no drugs suitable for the given
purpose and having the same active ingredient, dosage and
pharmaceutical form are already authorized [20]. France,
with Italy, is one of the ﬁrst countries permitting such prac-
tices. The grant of an RTU has been also extended beyond
three years, as it can be currently renewed. This could pre-
vent difﬁcult ends of RTUs, as it is impossible to force a ﬁrm
to submit a MA applicant dossier. At last, the term “conven-
tion” has been replaced by the term “protocol” which is less
binding, as RTUs are not supposed to require an approval
from the pharmaceutical ﬁrms. The European Commission
has approved the new decree that regulates RTU creation
[21].
4. Outstanding issues
As illustrated by the few number of RTUs that have been
granted to date, the RTU framework will not be able to
control all off-label uses, given the high number of clinical
situations that may  lead to an off-label prescription. There-
fore, communication on prescriptions for which the clinical
beneﬁt/risk ratio has been identiﬁed as unfavorable should
be reinforced. As suggested by a working group in 2012, we
support the creation of a national joint off-label commit-
tee that would be composed of representatives from the
ANSM, the French health technology assessment agency
ealth Po
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(Haute autorité de santé – HAS), the regional pharmacovigi-
lance centers, and from health authorities and the national
Social Security Insurance [22]. Among its possible mis-
sions and in addition to implement and monitor RTUs,
it would supervise off-label prescriptions by analyzing
existing databases, make a scientiﬁc watch, provide sup-
port for off-label prescriptions in public health indications,
implement education programs and communication tools.
Besides, from the experience of a regional team-based off-
label system for supervising baclofen prescribing [23], the
strict framework applied to the prescriptions under RTUs,
which is necessary for a national measure, should be coun-
teracted by expert centers that may  help physicians in
managing complicated clinical cases.
The main issue is that we can hypothesize that some
of these drugs will stay under this “temporary” status for
a while. Nothing is more uncertain than the process lead-
ing pharmaceutical companies to submit an extension of
the indication request, particularly given that they have
worldwide development strategies and that an RTU can be
shared with several ﬁrms. The three-year period was how-
ever too short for collecting enough data for a future MA
application’s ﬁle. In addition, the Euro compatibility has to
be clariﬁed. Our interpretation of the ECJ judgment (the
prohibition to prescribe drugs off their label when other
drugs “having the same active substances, the same dosage
and the same form (. . .)  are already authorized and avail-
able on the national market”) does not mean the opposite
is true, as stated in the amended RTU framework. Further-
more, the Court reminds that off-label uses are limited
for an individual patient under the physician’s responsi-
bility “relying solely on therapeutic considerations speciﬁc
to his patients”, whereas RTUs are granted at the national
level.
Regarding the controversial so-called “economic” RTUs,
the ANSM published in June 2015 an RTU for bevacizumab
(Table 1) despite the refusal of Roche to be accountable
for the use of its product in AMD. As it was recently
reminded by the ANSM, the implementation of an RTU
does not necessitate the endorsement of the ﬁrm, which
must nonetheless ensure and fund the patient monitoring.
As expected, litigation is currently opposing Roche against
the French health authorities, and at the time we write this
paper, the outcome of this conﬂict cannot be foreseen.
Finally, the adherence of the physicians to this new
control of their prescriptions that, it is important to reit-
erate, are under their sole responsibility, is uncertain. All
the more so the issue of the legal qualiﬁcation of RTUs
has not yet been clariﬁed. Their legal authority should
be based on the regulatory requirement for prescribers to
conform to a standard issued by the RTU, given the knowl-
edge acquired by science, when they prescribe outside a
MA [24]. However, tens of thousands of patients were tar-
geted by the RTU for baclofen but one year later, only 5300
patients are registered, mainly because of the constraints
imposed by the RTU on the criteria of inclusion and follow-
up [25]. In addition, the expected savings that could be
generated by the “economic” RTUs depend on how physi-
cians will support their non-clinical goal. Regarding this
speciﬁc case, we can assume that debates will be continued
[26].licy 119 (2015) 1399–1405
5. Conclusion
Most European countries do not have a formal or legal
framework to regulate off-label drug use, and even though
some initiatives have been identiﬁed [10], there is no coor-
dination at the EU level. France seems to be the only
country that requires an approval of the off-label use by
a national expert committee. Mainly because of the legal
challenges described above, it is premature to consider a
potential adaptation of the “economic” RTUs in the EU law.
Have the French health authorities opened a Pandora’s Box
by undermining the EU regulatory framework related to
the MA  and the incentives for manufacturer to perform
rigorous studies, as suggested by the pharmaceutical com-
panies [27]? Anyway, the bevacizumab/ranibizumab case
draws all the attention and may  hide the strengths of the
general cases covered by the RTU’s scope: the RTUs that
aimed at meeting a public health need by providing a reg-
ulated access to innovative drugs and to compassionate
uses. This framework controls off-label prescriptions for a
drug that already has MA,  ensures a favorable beneﬁt/risk
ratio, enables reimbursement, expands the scope of alert,
and has the capacity to reduce the scope of off-label pre-
scriptions [22]. This original approach should be carefully
tracked outside French borders by health care authorities
and decision-makers because this experience brings atten-
tion to the difﬁculties underlying an off-label use control.
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